Form 4: Artiva Biotherapeutics COO Reports RSU Grant, Tax Withholding

Artiva Biotherapeutics' COO, Jennifer Bush, reported the acquisition of 117,300 shares via a restricted stock unit award and the disposition of 3,515 shares for tax obligations.

Summary

• Jennifer Bush, COO, CLO, Secretary, and Compliance Officer of Artiva Biotherapeutics, Inc. (ARTV), reported changes in her beneficial ownership.
• She acquired 117,300 shares of common stock on February 15, 2026, as a restricted stock unit (RSU) award under the company's 2024 Equity Incentive Plan. The acquisition price was $0.
• Concurrently, she disposed of 3,515 shares of common stock on February 15, 2026, at a price of $4 per share. These shares were withheld by the Issuer to satisfy income tax obligations related to the vesting of RSU awards.
• Following these transactions, Jennifer Bush beneficially owns 346,710 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices that align management interests with shareholders, without indicating any immediate operational concerns.

Positives

• The grant of 117,300 restricted stock units to a key executive, Jennifer Bush, aligns her interests with shareholders and indicates continued commitment to the company.
• The RSU award is part of the company's 2024 Equity Incentive Plan, suggesting ongoing efforts to incentivize and retain key personnel.

Negatives

• The disposition of 3,515 shares, while for tax obligations, represents a reduction in direct ownership, albeit a small percentage of the total shares acquired.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the implication of ongoing executive incentive programs.

Industry Context

StockSavvy.ai notes that executive equity grants, such as restricted stock units, are a standard practice across the biotechnology and pharmaceutical industries. These grants are crucial for attracting and retaining top talent in a highly competitive sector, aligning executive incentives with long-term shareholder value creation. The tax withholding transaction is also a routine event associated with the vesting of such awards.

Related Party Transactions

• The grant of 117,300 restricted stock units to Jennifer Bush, a key executive, constitutes a related party transaction as it involves compensation from the issuer to an officer.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with shareholder interests, potentially fostering long-term value creation.
• Employees: The 2024 Equity Incentive Plan suggests a framework for employee incentives, potentially boosting morale and retention.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the grant of restricted stock units and subsequent tax-related share withholding. These transactions are standard practice and do not provide new fundamental information about Artiva Biotherapeutics' operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Artiva Biotherapeutics, ARTV, Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Incentive Plan, Executive Compensation, Jennifer Bush, Stock Award, Tax Withholding